Physicians' Academy for Cardiovascular Education

PCSK9 inhibition reduces atherogenic lipid levels in T2DM patients with mixed dyslipidemia

Alirocumab versus usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial

Literature - Ray KK, Leiter LA, Müller-Wieland D, et al. - Diab Obes Metabol 2018; published online ahead of print

Main results

The mean percentage changes from baseline to week 24 with alirocumab vs. UC were:

Results for the UC strata were similar to the overall analysis.

At week 24, more than two-thirds of alirocumab-treated individuals achieved levels of non-HDL-c <2.59 mmol/L (<100 mg/dL), LDL-c <1.81 mmol/L (<70 mg/dL) and ApoB <80 mg/dL. In addition, a greater proportion of individuals in the alirocumab group versus UC achieved a reduction in LDL-c from baseline of ≥50% (55.2% vs 3.8%).


In individuals with T2DM and mixed dyslipidemia who are not adequately controlled despite maximally tolerated statin therapy, the addition of the PCSK9 inhibitor alirocumab reduced more effectively their atherogenic lipid levels compared with the usual lipid-lowering therapeutic approaches.


Show references

Download the slide Find this article online at Diab Obes Metabol 2018

Click here to view the slide

Share this page with your colleagues and friends: